MedTrace Logo

The Importance of Muscle Function in Patients With Disseminated Bladder Cancer

NCT04144270 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2019-11-20

No results posted yet for this study

Summary

This study investigates if reduced muscle mass and muscle function predispose to poor completion of oncological treatment in patients with bladder cancer (including cancer of the renal pelvis, ureter and urethra) and if muscle mass and muscle function change during oncological treatment in these patients. It also evaluates biomarkers for sarcopenia.

Conditions

  • Urinary Bladder Neoplasm

Interventions

OTHER

Evaluation of muscle mass and muscle function

Included patients have their muscle mass and muscle function evaluated before start on and after completion of oncological treatment.

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Beckett Foundation

    collaborator OTHER

  • Onkologisk Forskningsfond

    collaborator UNKNOWN

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Lise Hoej Omland, MD · Rigshospitalet, Denmark

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-18
Primary Completion
2021-04-30
Completion
2021-04-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04144270 on ClinicalTrials.gov